All News
Filter News
Found 7,307 articles
-
Hepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference
3/22/2021
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, today announced its participation in the Benzinga Biotech Small Cap Conference on Thursday, March 25, 2021
-
INmune Bio, Inc. Announces Professor Mark Lowdell, PhD, CSO to Deliver Presentations at Two Upcoming Medical Meetings
3/22/2021
INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that Professor Mark Lowdell, PhD, Chief Scientific Officer of INmune Bio, will deliver presentations at two upcoming medical meetings.
-
Theratechnologies Announces New Data Demonstrating Tesamorelin’s Positive Effect on Immune Response Linked to Liver InflammationData presented at ENDO 2021
3/20/2021
Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that new data, demonstrating the positive effect of tesamorelin on the circulation of immune activation markers associated with liver inflammation, was presented at The Endocrine Society’s annual meeting, ENDO 2021.
-
89bio Presents Additional Analysis of Phase 1b/2a NASH Study at the Annual ENDO 2021 ConferenceNew analysis shows BIO89-100 meaningfully reduces liver fat volume and liver volume in patients with NASH
3/20/2021
89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, announced additional positive data from its Phase 1b/2a study of BIO89-100, a long-acting glycoPEGylated FGF21 analog, in patients with nonalcoholic steatohepatitis.
-
The U.S. Senate confirmed Xavier Becerra as Secretary of the Department of Health and Human Services in a 50-49 vote.
-
Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
3/19/2021
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced an interview with CEO Dr. Pnina Fishman will air on The RedChip Money Report® on the Bloomberg Network in the U.S. on Saturday, March 20th, at 7 p.m.
-
It will evaluate about 440 patients and the treatments’ effect on liver fibrosis improvement and NASH resolution.
-
Hepion PharmaceuticalsENDRA Life Sciences and Hepion Pharmaceuticals Partner to Drive Efficiencies in NASH Clinical Trials
3/18/2021
ENDRA Life Sciences Inc. , and Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) , a clinical-stage biopharmaceutical company focused on AI-driven therapeutic drug development for the treatment of NASH and liver disease, announced today the signing of a collaboration agreement
-
Metacrine Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
3/18/2021
Topline Results from a Phase 2a Trial of MET409 in Combination with Empagliflozin in Patients with NASH and Type 2 Diabetes Expected in the First Half of 2022
-
Gilead and Novo Nordisk Expand NASH Clinical Collaboration
3/18/2021
Gilead Sciences, Inc. and Novo Nordisk A/S announced that the companies have expanded their clinical collaboration in non-alcoholic steatohepatitis.
-
Can-Fite: Topical Administration of CF602 Fully Recovers Erectile Dysfunction in Diabetic Model
3/18/2021
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced new data from a preclinical study of its drug candidate CF602 in the treatment of erectile dysfunction in diabetes experimental model.
-
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2020 Financial Results
3/18/2021
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™
-
RNA-based Therapeutics and Vaccines Market | Know the factors that will hinder the growth of the market
3/18/2021
RNA-based biopharmaceuticals is a comparatively new class of treatment and it comprises vaccines and therapeutics.
-
Amathus Therapeutics, a biopharmaceutical company working on small molecule modulators across diverse genetically defined diseases, has entered into a strategic collaboration with Merck to develop novel small molecule treatment candidates for neurodegenerative diseases.
-
Axcella Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
3/17/2021
First IND application cleared by FDA for AXA1665 Initiation of AXA1665 Phase 2 clinical trial in OHE expected in Q2 2021 Initiation of AXA1125 Phase 2b clinical trial in NASH expected in Q2 2021 Company to host conference call at 8:30 a.m. ET today
-
Sequana Medical Announces 2020 Full Year Results and 2021 Outlook
3/17/2021
Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces its financial results for the year ended 31 December 2020, and provides a business update and an outlook for the remainder of 2021.
-
ENDRA Life Sciences to Report Fourth Quarter 2020 Financial Results on March 25, 2021
3/17/2021
ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the fourth quarter of 2020 on Thursday, March 25, 2021 after the close of trading on the U.S. financial markets.
-
Sagimet Biosciences Receives Fast Track Designation from U.S. Food and Drug Administration for FASN Inhibitor TVB-2640 in NASH
3/16/2021
In a recent Phase 2a trial, TVB-2640 improved serum biomarkers of liver injury in patients with nonalcoholic steatohepatitis (NASH)
-
Pliant Therapeutics Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner
3/16/2021
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the successful completion of a Phase 1 trial of PLN-1474, an oral, small-molecule selective inhibitor of the integrin α v β 1 in development for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis.
-
Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo-5MER
3/16/2021
- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company today announced the treatment of the first subject in the First-in-Human Phase I clinical trial